Join NBTS’s campaign to raise awareness about the importance of biomarker testing and clinical trials for patients with brain tumors.
READ MORE
On July 17, we commemorate the 6th annual Glioblastoma Awareness Day.
JOIN USPublished on May 10, 2024 in Press Release
Today, President Biden announced his intent to appoint four members to the National Cancer Advisory Board (NCAB), including Dr. Edjah Nduom, Chair of the National Brain Tumor Society’s Board of Directors.
Composed of 18 members from the health care, scientific, and public sectors, the NCAB plays an important role in guiding the Director of the National Cancer Institute (NCI) in setting the course for the national cancer research program in the United States. Serving six year terms, the members make recommendations for the support of grants and contract proposals as well as advise the NCI director on policy development, program implementation and evaluation, and research needs.
“I’m honored to represent the millions of Americans impacted by brain tumors every year and to serve as a voice for this community on this important board,” said Dr. Nduom. “I look forward to helping shape a robust agenda, including efforts to target the right treatments to the right patients. We also need to support and learn from patients, caregivers, and survivors and address healthcare inequities. And perhaps most importantly, we need to speed progress against the most deadly and rare cancers, including pediatric and adult brain tumors, which haven’t benefited from recent advances seen in other cancers. We must use our national resources to make sure that ALL of the diverse people of this nation have an opportunity to contribute to and benefit from this vital work.”
Dr. Nduom previously had the privilege of introducing President Biden at a White House event in 2022 to relaunch the Cancer Moonshot. He also participated in the first-ever White House Brain Cancers Forum on Glioblastoma and DIPG.
“We’re thrilled that Dr. Nduom has been selected for this prestigious advisory role that serves the U.S. cancer research enterprise at the highest level,” said David Arons, President and Chief Executive Officer of the National Brain Tumor Society. “This appointment is a testament to Dr. Nduom’s dedication and commitment to advancing high-quality, innovative, and equitable cancer care as well as his natural penchant for leadership and collaboration. We commend President Biden for recognizing Dr. Nduom’s unique qualifications to serve as a member of this board, as well as the need for brain tumor-specific expertise and experience on the NCAB. We know Dr. Nduom will represent the brain tumor and entire cancer community ably and proudly.”
Dr. Edjah Nduom holds the Daniel Louis Barrow Endowed Chair in Neurosurgery and is an associate professor in the Department of Neurosurgery at Emory University School of Medicine in Atlanta, Georgia. A fellowship-trained and board certified neurosurgical oncologist, Dr. Nduom’s clinical specialty is the surgical management of brain and spinal cord tumors. He holds numerous positions in national and international medical societies. Dr. Nduom received his MD from the University of Pennsylvania and his residency in Neurosurgery at Emory University. He completed a Research Fellowship in Neurosurgical Oncology in the Surgical Neurology Branch of the National Institute of Neurological Disorders and Stroke, and an additional Neurosurgical Oncology Fellowship at MD Anderson Cancer Center. He joined the National Brain Tumor Society Board of Directors in 2019, and was named its Chair in 2023.
TAGGED WITH: brain cancer, brain tumor, glioblastoma, brain tumor community, DIPG